Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept

Adam Mor, Clifton O. Bingham, Laura Barisoni-Thomas, Eileen Lydon, H. Michael Belmont

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Tumor necrosis factor-α (TNF-α) is a proinflammatory cytokine. Agents that neutralize TNF-α are effective in the treatment of disorders such as rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), spondyloarthropathies, and inflammatory bowel disease. TNF-α antagonist therapy has been associated with the development of antinuclear antibodies (ANA) and double-stranded DNA (dsDNA) antibodies, as well as the infrequent development of systemic lupus erythematosus (SLE)-like disease. We describe the first case of biopsy-confirmed proliferative lupus nephritis and leuko-cytoclastic vasculitis in a patient treated with etanercept for JRA.

Original languageEnglish
Pages (from-to)740-743
Number of pages4
JournalJournal of Rheumatology
Volume32
Issue number4
StatePublished - Apr 1 2005
Externally publishedYes

Fingerprint

Lupus Nephritis
Juvenile Arthritis
Tumor Necrosis Factor-alpha
Spondylarthropathies
Antinuclear Antibodies
Vasculitis
Inflammatory Bowel Diseases
Systemic Lupus Erythematosus
Rheumatoid Arthritis
Therapeutics
Cytokines
Biopsy
Antibodies
Etanercept
Erythema elevatum diutinum

Keywords

  • Etanercept
  • Nephritis
  • Systemic lupus erythematosus
  • Tumor necrosis factor
  • Vasculitis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. / Mor, Adam; Bingham, Clifton O.; Barisoni-Thomas, Laura; Lydon, Eileen; Belmont, H. Michael.

In: Journal of Rheumatology, Vol. 32, No. 4, 01.04.2005, p. 740-743.

Research output: Contribution to journalArticle

Mor, Adam ; Bingham, Clifton O. ; Barisoni-Thomas, Laura ; Lydon, Eileen ; Belmont, H. Michael. / Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. In: Journal of Rheumatology. 2005 ; Vol. 32, No. 4. pp. 740-743.
@article{00ef8d2441614800888b38d9453c594d,
title = "Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept",
abstract = "Tumor necrosis factor-α (TNF-α) is a proinflammatory cytokine. Agents that neutralize TNF-α are effective in the treatment of disorders such as rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), spondyloarthropathies, and inflammatory bowel disease. TNF-α antagonist therapy has been associated with the development of antinuclear antibodies (ANA) and double-stranded DNA (dsDNA) antibodies, as well as the infrequent development of systemic lupus erythematosus (SLE)-like disease. We describe the first case of biopsy-confirmed proliferative lupus nephritis and leuko-cytoclastic vasculitis in a patient treated with etanercept for JRA.",
keywords = "Etanercept, Nephritis, Systemic lupus erythematosus, Tumor necrosis factor, Vasculitis",
author = "Adam Mor and Bingham, {Clifton O.} and Laura Barisoni-Thomas and Eileen Lydon and Belmont, {H. Michael}",
year = "2005",
month = "4",
day = "1",
language = "English",
volume = "32",
pages = "740--743",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "4",

}

TY - JOUR

T1 - Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept

AU - Mor, Adam

AU - Bingham, Clifton O.

AU - Barisoni-Thomas, Laura

AU - Lydon, Eileen

AU - Belmont, H. Michael

PY - 2005/4/1

Y1 - 2005/4/1

N2 - Tumor necrosis factor-α (TNF-α) is a proinflammatory cytokine. Agents that neutralize TNF-α are effective in the treatment of disorders such as rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), spondyloarthropathies, and inflammatory bowel disease. TNF-α antagonist therapy has been associated with the development of antinuclear antibodies (ANA) and double-stranded DNA (dsDNA) antibodies, as well as the infrequent development of systemic lupus erythematosus (SLE)-like disease. We describe the first case of biopsy-confirmed proliferative lupus nephritis and leuko-cytoclastic vasculitis in a patient treated with etanercept for JRA.

AB - Tumor necrosis factor-α (TNF-α) is a proinflammatory cytokine. Agents that neutralize TNF-α are effective in the treatment of disorders such as rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), spondyloarthropathies, and inflammatory bowel disease. TNF-α antagonist therapy has been associated with the development of antinuclear antibodies (ANA) and double-stranded DNA (dsDNA) antibodies, as well as the infrequent development of systemic lupus erythematosus (SLE)-like disease. We describe the first case of biopsy-confirmed proliferative lupus nephritis and leuko-cytoclastic vasculitis in a patient treated with etanercept for JRA.

KW - Etanercept

KW - Nephritis

KW - Systemic lupus erythematosus

KW - Tumor necrosis factor

KW - Vasculitis

UR - http://www.scopus.com/inward/record.url?scp=17144368788&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17144368788&partnerID=8YFLogxK

M3 - Article

VL - 32

SP - 740

EP - 743

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 4

ER -